236 related articles for article (PubMed ID: 18007543)
1. BRCA screening.
Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
[No Abstract] [Full Text] [Related]
2. BRCA testing: ethics lessons for the new genetics.
Sherwin S
Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
[No Abstract] [Full Text] [Related]
3. [Genetic testing in patients at risk for carcinoma of the breast].
Kiechle M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
[No Abstract] [Full Text] [Related]
4. BRCA1 and BRCA2 mutations in a South American population.
Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM
Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
6. Variability in Cancer Risk with BRCA Mutations.
Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
[No Abstract] [Full Text] [Related]
7. [Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer].
Rumiantseva UV; Rumiantsev PO; Kiseleva MV
Vopr Onkol; 2008; 54(3):251-9. PubMed ID: 18652227
[No Abstract] [Full Text] [Related]
8. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
9. The case against BRCA 1 and 2 testing.
Lin C; Sasaki T; Strumwasser A; Harken A
Surgery; 2011 Jun; 149(6):731-4. PubMed ID: 21621683
[No Abstract] [Full Text] [Related]
10. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
[TBL] [Abstract][Full Text] [Related]
11. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
12. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
14. The expanding role of genetics in contraception and women's health.
Shulman LP; Shields W
Contraception; 2005 Feb; 71(2):81-3. PubMed ID: 15707554
[No Abstract] [Full Text] [Related]
15. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P; Voigtlaender T; Bartram CR; Klaes R
Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
[TBL] [Abstract][Full Text] [Related]
16. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
Bodmer D; Ligtenberg MJ; van der Hout AH; Gloudemans S; Ansink K; Oosterwijk JC; Hoogerbrugge N
Br J Cancer; 2006 Sep; 95(6):757-62. PubMed ID: 16909138
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
18. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
[No Abstract] [Full Text] [Related]
19. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Kauff ND
J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
[No Abstract] [Full Text] [Related]
20. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
[No Abstract] [Full Text] [Related]
[Next] [New Search]
